CBU
AXSM icon

CIBC Bancorp USA’s Axsome Therapeutics AXSM Stock Holding History

CIBC Bancorp USA’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.56M Sell
10,465
-4,998
-32% -$1.08M ﹤0.01% 913
2026
Q1 		$2.61M Buy
+15,463
New +$2.67M ﹤0.01% 857
2025
Q3 		$524K Buy
+4,314
New +$486K ﹤0.01% 848

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CIBC Bancorp USA's AXSM Position: Q2 2026 in Review

CIBC Bancorp USA reduced its Axsome Therapeutics (AXSM) stake by 32% in Q2 2026, selling an estimated $1.08M and leaving 10,465 shares worth $2.56M. The position accounts for ﹤0.01% of the portfolio, ranked #913.

CIBC Bancorp USA first reported a position in AXSM in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.61M in Q1 2026. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • CIBC Bancorp USA held 10,465 shares of Axsome Therapeutics worth $2.56M as of Q2 2026.
  • CIBC Bancorp USA sold 4,998 Axsome Therapeutics shares in Q2 2026, an estimated $1.08M.
  • Axsome Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #913 holding.
  • CIBC Bancorp USA first reported a position in Axsome Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • CIBC Bancorp USA's Axsome Therapeutics position peaked at $2.61M in Q1 2026.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.